Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo controlled randomized trial in healthcare workersResearch article Published on 2022-08-012022-10-05 Journal: Clinical microbiology and infection : the official [Category] SARS, 신약개발, 임상, [키워드] 95% CI 95% CIs Adverse assigned Asymptomatic benefit Combination conducted COVID-19 Daily double-blind eligible event generally mild group HCQ healthcare worker Hydroxychloroquine IgM/IgG individual laboratory-confirmed objective outcome Placebo placebo group placebo-controlled randomized trial pre-exposure prophylaxis Prophylaxis randomized clinical trial randomized trial Randomly Result risk risk ratio Sample size SARS-CoV-2 screened Spain symptomatic TDF/FTC tenofovir tenofovir disoproxil Venezuela was performed [DOI] 10.1016/j.cmi.2022.07.006 [Article Type] Research article
Noradrenergic Add-on Therapy with Extended-Release Guanfacine in Alzheimer’s Disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments알츠하이머병(NorAD)에서 연장 방출 구안파신을 사용한 노르아드레날린성 추가 요법: 무작위 임상 시험 및 COVID-19 수정안에 대한 연구 프로토콜Article Published on 2022-08-012022-09-11 Journal: Trials [Category] 임상, [키워드] activities activity Add-on therapy addition Adrenergic receptor affected Alzheimer's disease Alzheimer’s disease approved assessment Attention attention deficit baseline Brain burden cholinesterase inhibitor clinical trial Cognition cognitive Combination combination therapy COVID-19 Daily daily living determine disease disorder double-blind dysfunction evaluate Evidence executive Follow-up function Guanfacine Guanfacine. hyperactivity IMPROVE include interview inventory involved locus measure Mild mild to moderate moderate modulating Neuropsychiatric NorAD noradrenergic observation outcome participant pathological change pathological changes pathway Pathways Placebo placebo group placebo-controlled Primary outcome randomised receive receptor Regulation secondary Secondary outcomes Study protocol Symptom symptomatic synergistic synergistic effect Test the placebo group thought Treatment treatment group Trial [DOI] 10.1186/s13063-022-06190-3 PMC 바로가기 [Article Type] Article
Estimation of vaccine efficacy for variants that emerge after the placebo group is vaccinated위약군 백신 접종 후 나타나는 변이체에 대한 백신 효능 추정Article Published on 2022-07-202022-09-11 Journal: Statistics in medicine [Category] COVID19(2023년), SARS, 변종, 임상, [키워드] approach assumption clinical trial Cox regression demonstrated develop distribution Effects Efficacy estimation evaluate Follow-up hazard illustration misspecification Observational data Placebo placebo group Poisson proportion proportional hazards model proportions Randomized rare disease reflect SARS-CoV-2 Sensitivity analyses sensitivity analysis sieve analysis strain Strains Surveillance surveillance data the placebo group the vaccine vaccination Vaccine vaccine efficacy vaccine trial vaccine. variant variants [DOI] 10.1002/sim.9405 PMC 바로가기 [Article Type] Article
Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trialClinical Trial Published on 2022-07-082022-10-05 Journal: The Lancet. Respiratory Medicine [Category] 임상, 진단, 치료법, [키워드] 1:1 addition adverse event analysis assigned baseline Cohort Complete COVID-19 cumulative defined double-blind Europe extracorporeal membrane oxygenation finding Follow-up funding hazard ratio hospital discharge hospitalised hypothesised IMPROVE incidence infused intravenous Invasive mechanical ventilation investigators modified intention-to-treat monoclonal antibody combination Mortality neutralising NIH occurred operation Organ failure outcome participant Patient Phase 3 phase 3 trial Placebo placebo group placebo-controlled trial Primary outcome randomised Randomly receive receiving Registered Remdesivir renal replacement therapy Result Safe seronegative Singapore speed standard care study drug Study participants Support sustained Symptom the placebo group therapy Treatment Uganda USA were excluded with COVID-19 [DOI] 10.1016/S2213-2600(22)00215-6 [Article Type] Clinical Trial
Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response Research Published on 2022-07-082022-10-05 Journal: Scientific Reports [Category] Coronavirus, 임상, [키워드] amplitude baseline candidate change children control groups correlated demonstrated Efficacy ERG evaluate evaluated identify intervals likelihood opposite placebo group placebo-controlled clinical trial placebo-controlled trial positively correlated progression protocol Randomized reduce statistical significance the placebo group Treatment response was measured were measured [DOI] 10.1038/s41598-022-15686-6 [Article Type] Research
Hydroxychloroquine versus placebo in the treatment of non-hospitalised patients with COVID-19 (COPE – Coalition V): A double-blind, multicentre, randomised, controlled trialResearch article Published on 2022-07-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 신약개발, 임상, 치료법, [키워드] 1:1 Analysis benefit Brazil Chloroquine Clinical deterioration Coalition complement conducted Controlled trial COPE COVID-19 COVID-19 patient did not reduce double-blind Enrollment events finding form funding hospitalisation Hydroxychloroquine Infection intention-to-treat ITT matching placebo Meta-analysis Mild mITT analysis moderate molecular multicenter multicentre no significant difference non-hospitalised Outpatient participants with SARS-CoV-2 Patient patients with COVID-19 Placebo placebo group positive precluded presenting Primary outcome randomised Randomly RCT receive reducing Registered risk risk factor serology testing Seven Statistical power suggested Support Symptom Treatment treatment allocation Trial use of hydroxychloroquine was performed [DOI] 10.1016/j.lana.2022.100243 [Article Type] Research article
Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled TrialRandomized Controlled Trial Published on 2022-07-012022-10-05 Journal: Chest [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 28-day mortality activity acute respiratory symptom adjusted odds ratio adults hospitalized analyzed anti-SARS-CoV-2 antibodies anti-SARS-CoV-2 antibody antibody assigned blinded clinical clinical status clinical trial convalescent plasma convalescent plasma group COVID-19 death died discharged Efficacy groups highest hospital Illness severity improve clinical outcomes lowest multicenter multivariable Neutralizing not differ outcome outcomes passive immunity Patient Placebo placebo group placebo-controlled plasma primary analysis Primary outcome randomization randomized clinical trial randomized patients Randomly receive Registration Regression model Result SARS-CoV-2 SARS-COV-2 infection Secondary analyses selected seronegative seven-category ordinal scale stratified supported the placebo group Treatment treatments for COVID-19 Trial trial participant with COVID-19 [DOI] 10.1016/j.chest.2022.06.029 [Article Type] Randomized Controlled Trial
Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19Covid-19 예방을 위한 근육주사 AZD7442(Tixagevimab-Cilgavimab)Clinical Trial Published on 2022-06-092022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 비임상, 신약개발, 임상, 진단, 치료제, [키워드] 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 administration adverse event adverse events age animal models assigned AstraZeneca breath cilgavimab Combination composed conducted coronavirus coronavirus disease Coronavirus disease 2019 Critical death dose Efficacy efficacy end point end point enrolled exposure to Follow-up Human incidence increased risk intramuscular injections median Mild moderate Neutralizing antibodies neutralizing antibody occurred participant pharmacokinetic data phase 3 trial Placebo placebo group prevention primary analysis Prophylactic randomization Randomized Randomly receive Relative risk reported respiratory response to vaccination risk reduction saline placebo SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus severity shown single dose symptomatic COVID-19 the placebo group therapeutic effect Tixagevimab [DOI] 10.1056/NEJMoa2116620 PMC 바로가기 [Article Type] Clinical Trial
The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trialRandomized Controlled Trial Published on 2022-06-062022-10-05 Journal: Trials [Category] 임상, [키워드] Affect anti-inflammatory agent approved biochemical blood glucose changes in clinical Clinical symptoms clinical trial complete blood count cough COVID-19 COVID-19 complications COVID-19 pandemic creating CRP Curcumin disease double-blind dry cough Dyspnea effective Efficacy headache Health Health status Inflammatory factor Kidney function liver enzymes medication muscular pain not significantly different Outpatient p value parameters patients with COVID-19 piperine Piperine. Placebo placebo group placebo-controlled trial positive Protein Randomized Randomly receive reduce registry severity significantly sore throat sputum the disease two groups weakness with COVID-19 [DOI] 10.1186/s13063-022-06375-w PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine재조합 식물 기반 면역증강제 코로나19 백신의 효능 및 안전성Clinical Trial Published on 2022-06-022022-09-11 Journal: The New England Journal of Medicine [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, 치료제, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant adverse event age Analysis AS03 assigned baseline candidate vaccine caused conducted coronavirus coronavirus disease Coronavirus disease 2019 CoVLP CoVLP+AS03 determine disease dose effective Efficacy Factor FIVE incidence injection intention-to-treat intention-to-treat population Intramuscular injection Local median age Median viral load Medicago Mild moderate occurred participant Participants participated Particle performed Phase 3 Placebo placebo group placebo-controlled trial plant plants polymerase Post hoc analysis prefusion produced Randomized receive recombinant respiratory Safety SARS-CoV-2 sequenced Sequencing seronegative severe acute respiratory syndrome Coronavirus Severe case Spectrum spike glycoprotein symptomatic symptomatic COVID-19 symptomatic infection System systemic adverse event systemic adverse events the median the placebo group the vaccine Trial two group two groups Vaccine vaccine efficacy vaccine group variant variants Viral Viral load viral sample Volunteer [DOI] 10.1056/NEJMoa2201300 PMC 바로가기 [Article Type] Clinical Trial